Navigation Links
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update

Peramivir was generally safe and well-tolerated at these dose levels.

Detailed results will be submitted to an upcoming medical meeting.

-- BioCryst reported top-line results from the completed Phase 2a trial of

BCX-4208 in subjects with moderate to severe plaque psoriasis were

consistent with interim findings. BCX-4208, a potent, rationally

designed, orally available purine nucleoside phosphorylase inhibitor,

met its primary endpoint of safety and tolerability and displayed

dose-dependant reductions in peripheral blood lymphocyte counts. The

pharmacokinetic and pharmacodynamic results suggest that BCX-4208 may

have utility in diseases dependant on T-cells, B-cells or uric acid.

The Phase 2a results have been accepted for presentation at the 50th

American Society of Hematology Annual Meeting and Exposition (ASH),

which will be held in San Francisco, December 6-9, 2008.

-- The forodesine HCl pivotal trial in cutaneous T-cell lymphoma (CTCL)

continues to enroll subjects with CTCL stages IIB through IVA who have

failed three systemic therapies. The multinational study is evaluating

once daily oral forodesine HCL treatment and is being conducted in

accordance with a Special Protocol Assessment agreement between the U.S.

Food and Drug Administration and BioCryst. A laboratory study of

forodesine HCl in leukemia cells has been accepted for presentation at


Conference Call and Web cast

BioCryst's management team will host a conference call and Web cast on Friday, October 31, 2008, at 8:30 a.m. Eastern Time to discuss the financial results and recent developments within the Company's programs. To participate in the conference call, please dial 1-800-860-2442 (United States) or 1-412-858-4600 (International). No passcode is needed for the call. The Web ca

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
2. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
3. BioCryst to Present at the JMP Healthcare Focus Conference
4. BioCryst to Present at UBS 2008 Global Life Sciences Conference
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
9. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
10. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
11. BioCryst to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Sept. 13 Genomatica announced today that ... company full time as executive chairman and chief business ... leading chemical producers, users, feedstock suppliers, brands and retailers. ... biotech leadership; $500 million in partnerships ...
... 10 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ... all of the Company,s outstanding 2.75% Convertible Subordinated Notes, due ... Notes have been provided notice of the redemption by the ... holders who elect to convert their 2023 Notes into the ...
... Paratek Pharmaceuticals, Inc. today announced the Company,s lead ... the subject of several poster presentations at the ... (ICAAC).  Dr. Stuart Levy, co-founder and Chief Scientific ... talk at a symposium on antibiotic resistance at ...
Cached Biology Technology:Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 2Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 3Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 4PDL BioPharma Provides Clarification Regarding Redemption of Its 2.75% Convertible Subordinated Notes 2Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy 3
(Date:12/17/2014)... 16, 2014  Automation is fundamentally transforming the ... than at international borders. Over the past decade, ... allowed veteran travelers to self process through border ... Kiosks at an increasing number of airports, seaports, ... According to Maxine Most , Principal ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... -- A two-year study of college students at ... learn better and develop higher-level skills by participating ... teaching methods. Elsa Snchez and Richard Craig, ... surveyed students enrolled from 2003-2005 in their Plant ...
... -- We love it fresh, canned and frozen. It,s grown ... by the American Society of Horticultural Science, adds up to ... In other words, sweet corn is big business. Fresh ... July, with only ten percent of the annual volume marketed ...
... Two common dietary molecules found in legumes and ... of radiation, researchers from the University of Maryland ... human skin cells and a skin cancer-prone mouse ... damaging radiation found in sunlight, the team reported ...
Cached Biology News:Teamwork improves learning and career success 2How sweet is it? 2Antioxidants could provide all-purpose radiation protection 2Antioxidants could provide all-purpose radiation protection 3
Ideal for chemical processing that requires downward flow of exhaust fumes. Powderful 1200 CFM blower draws fumes into sub-surface bonded charcoal filter for safe removal of organic vapors (final HEP...
... Shimadzus preparative LC/MS, using mass numbers as ... it ideal for performing investigation and research ... for both analytical and preparative operation. Switching ... in the software. This support provides a ...
... Label IT siRNA Tracker Intracellular Localization Kit ... label and deliver siRNA, of your design, ... in vitro tracking experiments. Subcellular localization and ... be monitored following introduction of the labeled ...
Selective media for Salmonella...
Biology Products: